Table 1 Demographic and clinical characteristics of the study population. HBsAg, hepatitis B surface antigen; Anti-HCV, antibody against hepatitis C virus; ECOG, eastern cooperative oncology group; AFP, alpha-fetoprotein; TNM, tumor, node, and metastasis.
From: Serum fibronectin distinguishes the early stages of hepatocellular carcinoma
Training set | Test set | Validation set | |||||
|---|---|---|---|---|---|---|---|
LC | HCC/Recovery | LC | HCC/Recovery | LC | HCC/Recovery | ||
(n = 30) | (n = 30/30) | (n = 30) | (n = 30/30) | (n = 20) | (n = 20/20) | ||
Age (years) | 58.97 ± 8.07 | 57.83 ± 10.21 | 55.33 ± 9.77 | 62.50 ± 9.38 | 55.00 ± 7.13 | 57.00 ± 10.17 | |
Gender | Male | 19 | 24 | 2 | 21 | 0 | 18 |
Female | 11 | 6 | 28 | 9 | 20 | 2 | |
Etiology | HBsAg-positive | 21 | 21 | 17 | 21 | 16 | 15 |
Anti-HCV-positive | 1 | 3 | 2 | 4 | 1 | 1 | |
Alcohol | 8 | 6 | 11 | 5 | 3 | 4 | |
ECOG | 0 | 29 | 29 | 30 | 29 | 20 | 20 |
1 | 1 | 1 | 0 | 1 | 0 | 0 | |
AFP (ng/mL) | <20 | 25 | 21 | 29 | 21 | 20 | 13 |
≥20 | 5 | 9 | 1 | 9 | 0 | 7 | |
Tumor size (cm) | <5 | 29 | 27 | 17 | |||
≥5 | 1 | 3 | 3 | ||||
Tumor number | <3 | 30 | 28 | 19 | |||
≥3 | 0 | 2 | 1 | ||||
Metastasis | No | 30 | 30 | 20 | |||
Yes | 0 | 0 | 0 | ||||
TNM stage | 0 | 0 | 0 | 0 | |||
I | 27 | 23 | 17 | ||||
II | 3 | 7 | 3 | ||||
III | 0 | 0 | 0 | ||||
IV | 0 | 0 | 0 | ||||
